Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Clinical significance of S100A2 expression in gastric cancer

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Gastric carcinoma (GC) is one of the most common malignancies worldwide. To identify the candidate carcinoma-related biomarker in GC, comparative proteome technique was performed in resected GC tissues and matched adjacent non-cancerous gastric tissues (ANGT). As a result, S100A2 was successfully identified to be down-regulated significantly in GC compared with ANGT. Western blot analysis validated decreased expression of S100A2, and its expression level was related with the degree of tumor differentiation and status of lymph node metastasis in GC. Furthermore, immunohistochemistry analysis showed S100A2 down-expression was significantly associated with poor differentiation (P < 0.05), advanced depth of invasion (P < 0.05) and lymph node metastasis (P < 0.05) in GC. Kaplan–Meier curves showed that the relapse-free probability and the overall survival rate were significantly decreased with S100A2 expression decreasing (P < 0.05). Cox regression analysis indicated S100A2 down-expression was a negative independent prognostic biomarker for GC. A supplement of S100A2 protein by S100A2 expression vector significantly decreased the number of invaded cancer cells MGC-803. However, knockdown of S100A2 expression by siRNA interference compromised the invasion ability of MGC-803 cells. Moreover, S100A2 negatively regulated MEK/ERK signaling pathway, and activation of this signaling pathway by S100A2 down-regulation increased in vitro invasion of MGC-803 cells. In conclusion, this study demonstrated the clinical significance of S100A2 expression in GC, and loss of S100A2 expression contributes to GC development and progression. Therefore, the determination of S100A2 expression levels contributes to predict the outcome of GC patients.
Literature
1.
Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–77.PubMedCrossRef
2.
3.
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J. 2006;396(2):201–14.PubMedCentralPubMedCrossRef
4.
Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356–68.PubMedCrossRef
5.
6.
7.
Deshpande R et al. Biochemical characterization of S100A2 in human keratinocytes: subcellular localization, dimerization, and oxidative cross-linking. J Invest Dermatol. 2000;115(3):477–85.PubMedCrossRef
8.
9.
Almadori G et al. Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2009;38(1):16–22.PubMed
10.
Feng G et al. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res. 2001;61(21):7999–8004.PubMed
11.
Nagy N et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest. 2001;81(4):599–612.PubMedCrossRef
12.
Bronckart Y et al. Development and progression of malignancy in human colon tissues are correlated with expression of specific Ca(2+)-binding S100 proteins. Histol Histopathol. 2001;16(3):707–12.PubMed
13.
Shrestha P et al. Localization of Ca(2+)-binding S100 proteins in epithelial tumours of the skin. Virchows Arch. 1998;432(1):53–9.PubMedCrossRef
14.
El-Rifai W et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62(23):6823–6.PubMed
15.
Bulk E et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009;15(1):22–9.PubMedCrossRef
16.
Ohuchida K et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol. 2007;213(3):275–82.PubMedCrossRef
17.
Smith SL et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer. 2004;91(8):1515–24.PubMedCentralPubMed
18.
Liu YF et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217(1):54–64.PubMedCrossRef
19.
Liu YF et al. Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis. 2011;28(5):413–25.PubMedCrossRef
20.
Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003;22(4):395–403.PubMedCrossRef
21.
Welch DR et al. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res. 2000;60(6):1552–6.PubMed
22.
Ward Y et al. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol. 2001;21(17):5958–69.PubMedCentralPubMedCrossRef
23.
Wolf S, Haase-Kohn C, Pietzsch J. S100A2 in cancerogenesis: a friend or a foe? Amino Acids. 2011;41(4):849–61.PubMedCrossRef
24.
Wicki R et al. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium. 1997;22(4):243–54.PubMedCrossRef
25.
Maelandsmo GM et al. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer. 1997;74(4):464–9.PubMedCrossRef
26.
Ji J et al. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130(8):480–6.PubMedCrossRef
27.
Zhang X et al. Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Head Neck. 2007;29(3):236–43.PubMedCrossRef
28.
Matsumoto K et al. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 2007;70(3):602–7.PubMedCrossRef
29.
Kyriazanos ID et al. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. Oncol Rep. 2002;9(3):503–10.PubMed
30.
Lauriola L et al. Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer. 2000;89(4):345–9.PubMedCrossRef
31.
Hountis P et al. Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma. Onco Targets Ther. 2012;5:363–73.PubMedCentralPubMedCrossRef
32.
Luo J et al. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma. Diagn Cytopathol. 2011;39(10):752–7.PubMedCrossRef
33.
Lapi E et al. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene. 2006;25(26):3628–37.PubMedCrossRef
34.
Mueller A et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem. 2005;280(32):29186–93.PubMedCrossRef
Metadata
Title
Clinical significance of S100A2 expression in gastric cancer
Publication date
01-04-2014
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1495-3

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

Research Article

Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility

Research Article

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

Research Article

Change in expression of cyclin G2 in kidney cancer cell and its significance

Research Article

Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma

Research Article

Haplotype-based case–control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits